PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer

In three large clinical trials of women with newly diagnosed ovarian cancer, treatment with a PARP inhibitor as first-line therapy, maintenance therapy, or both, the delayed the length of time before participants’ cancers came back or got worse.

from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2Jw6Mex